Rite Aid Corporation (NYSE: RAD) stock opened higher on Friday and is recovering from the multi-year low on August 15. Investors turned optimistic about the future after upbeat second-quarter results. The drugstore chain remained under the hands of new CEO Heyward Donigan, who is likely to aid in achieving growth in the upcoming quarters.
The company has in the past been struggling to survive in the drugstore industry due to stiff competition. Rite Aid refocused its strategy to adapt its business segments like eCommerce and drug store prescription fillings. As part of ongoing business activities, the company assesses stores and distribution centers for potential closure or relocation.
Retail remained the main focus of Rite Aid with a majority of the revenue was coming through the sale of prescription drugs and front-end products at the company’s 2,464 retail stores. However, the company has been facing a shortfall in the stores’ traffic due to mounting pressure from e-commerce. Hence, the company opted for store closing in order to face higher costs and expenses.
The margins were hurt by reimbursement rate declines despite generic purchasing efficiencies and the increase in same-store prescription count. The company has strong labor and expense control at the stores as well as labor savings and expense management relating to the recent corporate restructuring. This has aided in the bottom-line growth, which is expected to continue in the future.
For the second quarter, the company swung to a profit from a loss last year, helped by lower costs and expenses. In the Retail Pharmacy segment, revenues edged down 1.6% hurt by store closures, even though same-store sales modestly increased 0.4%. Pharmacy sales have been negatively impacted by new generic introductions.
As of August 31, 2019, Rite Aid has $142.18 million of cash and cash equivalents while long-term debt stood at $3.83 billion and the accumulated deficit remained at $4.95 billion. The company has been aggressive in financing its growth with debt due to high risk. The share value is pressurized by the cost of debt financing outweighing the bottom-line results.
The company plans to use cash flow from operations along with available borrowings and other sources of liquidity for meeting working capital, debt, and capital expenditures requirements until the end of next year. Rite Aid’s liquidity position is expected to remain strong throughout fiscal 2020.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
Comments
Comments are closed.